Cargando…

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091524/ https://www.ncbi.nlm.nih.gov/pubmed/25057448 http://dx.doi.org/10.4161/onci.28861

Ejemplares similares

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
por: Ohyashiki, Junko H, et al.
Publicado: (2014)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2017)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27
por: Xu, Mingli, et al.
Publicado: (2010)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2018)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2015)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2016)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner
por: Chiba, Yukino, et al.
Publicado: (2013)

Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis
por: Furusawa, Jun-ichi, et al.
Publicado: (2016)

Potential clinical application of interleukin-27 as an antitumor agent
por: Yoshimoto, Takayuki, et al.
Publicado: (2015)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

A Pivotal Role for Interleukin-27 in CD8(+) T Cell Functions and Generation of Cytotoxic T Lymphocytes
por: Morishima, Noriko, et al.
Publicado: (2010)

Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma
por: Katagiri, Seiichiro, et al.
Publicado: (2017)

Regulation of inflammatory immune responses leading to the development of bone destructive autoimmune disease rheumatoid arthritis by IL-27
por: Yoshimoto, Takayuki, et al.
Publicado: (2012)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Age-related decrease of miRNA-92a levels in human CD8(+ )T-cells correlates with a reduction of naïve T lymphocytes
por: Ohyashiki, Michiyo, et al.
Publicado: (2011)

MORPHOLOGIC CHANGES OF NEUTROPHILS IN MYELODYSPLASTIC SYNDROME TREATED WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR
por: Toyama, Keisuke, et al.
Publicado: (1988)

Non‐radioisotopic and Semi‐quantitative Procedure for Terminal Repeat Amplification Protocol
por: Ohyashiki, Junko H., et al.
Publicado: (1996)

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
por: Ohyashiki, Kazuma, et al.
Publicado: (1989)

Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation
por: Yoshizawa, Seiichiro, et al.
Publicado: (2018)

Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases
por: Qu, Ning, et al.
Publicado: (2013)

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008)

Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family
por: Hasegawa, Hideaki, et al.
Publicado: (2016)

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
por: Ohyashiki, Junko H, et al.
Publicado: (2012)

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
por: Imanishi, Satoshi, et al.
Publicado: (2018)

Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis
por: Gladkova, Nina, et al.
Publicado: (2020)

T cell immunosurveillance controls B lymphoma development
por: Kallies, Axel
Publicado: (2014)

The dual role of IRF8 in cancer immunosurveillance
por: Schiavoni, Giovanna, et al.
Publicado: (2013)

Evasion before invasion: Pre-cancer immunosurveillance
por: Angelova, Mihaela, et al.
Publicado: (2021)

Cellular senescence enhances adaptive anticancer immunosurveillance
por: Marin, Ines, et al.
Publicado: (2022)

Prediction of Chemical Respiratory and Contact Sensitizers by OX40L Expression in Dendritic Cells Using a Novel 3D Coculture System
por: Mizoguchi, Izuru, et al.
Publicado: (2017)

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients
por: Tanaka, Masami, et al.
Publicado: (2009)

Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
por: Ohyashiki, Kazuma, et al.
Publicado: (2011)

Immunosurveillance of senescent cancer cells by natural killer cells
por: Iannello, Alexandre, et al.
Publicado: (2014)

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
por: Ohyashiki, Junko H, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_o8boe6nkd6c49s0ssdc0673r82